SG10201914117QA - Treatment Of Myelosuppression - Google Patents

Treatment Of Myelosuppression

Info

Publication number
SG10201914117QA
SG10201914117QA SG10201914117QA SG10201914117QA SG10201914117QA SG 10201914117Q A SG10201914117Q A SG 10201914117QA SG 10201914117Q A SG10201914117Q A SG 10201914117QA SG 10201914117Q A SG10201914117Q A SG 10201914117QA SG 10201914117Q A SG10201914117Q A SG 10201914117QA
Authority
SG
Singapore
Prior art keywords
treatment
myelosuppression
treatment regimens
thrombopoies
administering
Prior art date
Application number
SG10201914117QA
Inventor
Stephen Marcus
Original Assignee
Cantex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantex Pharmaceuticals Inc filed Critical Cantex Pharmaceuticals Inc
Publication of SG10201914117QA publication Critical patent/SG10201914117QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

Treatment Of Myelosuppression Methods are presented for attenuating myelosuppressive side effects of treatment regimens, promoting thrombopoies is and neutrophil production, and increasing efficacy of treatment regimens, by administering PF4-interacting heparinoids. [Figure 13A]
SG10201914117QA 2012-05-09 2013-03-13 Treatment Of Myelosuppression SG10201914117QA (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261644556P 2012-05-09 2012-05-09
US201261644623P 2012-05-09 2012-05-09
US201261648043P 2012-05-16 2012-05-16
US201261653362P 2012-05-30 2012-05-30
US201261664611P 2012-06-26 2012-06-26
US201261668709P 2012-07-06 2012-07-06
US201261678053P 2012-07-31 2012-07-31
US201261702207P 2012-09-17 2012-09-17
US201261724836P 2012-11-09 2012-11-09

Publications (1)

Publication Number Publication Date
SG10201914117QA true SG10201914117QA (en) 2020-02-27

Family

ID=49549076

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201603059YA SG10201603059YA (en) 2012-05-09 2013-03-13 Treatment Of Myelosuppression
SG11201407340YA SG11201407340YA (en) 2012-05-09 2013-03-13 Treatment of myelosuppression
SG10201914117QA SG10201914117QA (en) 2012-05-09 2013-03-13 Treatment Of Myelosuppression

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG10201603059YA SG10201603059YA (en) 2012-05-09 2013-03-13 Treatment Of Myelosuppression
SG11201407340YA SG11201407340YA (en) 2012-05-09 2013-03-13 Treatment of myelosuppression

Country Status (21)

Country Link
US (6) US9271999B2 (en)
EP (2) EP3785720A1 (en)
JP (3) JP6177885B2 (en)
KR (2) KR102452803B1 (en)
CN (3) CN108498532B (en)
AU (1) AU2013260101B2 (en)
BR (1) BR112014028094B1 (en)
CA (2) CA2872855C (en)
CL (2) CL2014003017A1 (en)
DK (1) DK2846809T3 (en)
EA (1) EA029382B1 (en)
ES (1) ES2848050T3 (en)
HK (1) HK1207574A1 (en)
HU (1) HUE053247T2 (en)
IL (1) IL235593B (en)
LT (1) LT2846809T (en)
MX (2) MX370567B (en)
PL (1) PL2846809T3 (en)
PT (1) PT2846809T (en)
SG (3) SG10201603059YA (en)
WO (1) WO2013169355A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE053247T2 (en) 2012-05-09 2021-06-28 Cantex Pharmaceuticals Inc Treatment of myelosuppression
AU2014340238A1 (en) * 2013-10-22 2016-05-05 Cantex Pharmaceuticals, Inc. Methods of treating and preventing radiation damage
WO2015142924A1 (en) 2014-03-17 2015-09-24 Cantex Pharmaceuticals, Inc. Multivalent cation formulations of partially desulfated heparins
EP3258941A4 (en) * 2015-02-17 2018-09-26 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
BR112017018954A2 (en) 2015-03-06 2018-05-15 Beyondspring Pharmaceuticals, Inc. Use of Ras Protein Mutant Form and Method to Treat Cancer
EP3334726B1 (en) 2015-07-13 2022-03-16 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
RU2753543C1 (en) 2016-02-08 2021-08-17 Бейондспринг Фармасьютикалс, Инк. Compositions containing tucaresol or analogues thereof
RU2760348C2 (en) 2016-06-06 2021-11-24 Бейондспринг Фармасьютикалс, Инк. Method for reducing neutropenia
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
SG11201907023UA (en) 2017-02-01 2019-08-27 Beyondspring Pharmaceuticals Inc Method of reducing neutropenia
CN107569486A (en) * 2017-08-23 2018-01-12 北京京佑奇康生物科技有限公司 Menglusitena treats the new application of thrombopenia
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3743074A4 (en) * 2018-01-24 2021-12-15 Beyondspring Pharmaceuticals Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
MA54821A (en) * 2019-01-25 2021-12-01 Janssen Pharmaceutica Nv METHODS FOR INCREASING PROTECTION AGAINST ORGAN AND VESSEL DAMAGE, HEMATOPOIETIC RECOVERY AND SURVIVAL IN RESPONSE TO EXPOSURE TO WHOLE BODY IRRADIATION OR CHEMICAL AGENTS
KR20220009954A (en) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 Neurocognitive Disorder, How to Treat Chronic Pain and Reduce Inflammation
US20220305048A1 (en) * 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
EP4058018A4 (en) * 2019-11-13 2023-06-21 Taiho Pharmaceutical Co., Ltd. Methods of treating lsd1-related diseases and disorders with lsd1 inhibitors
WO2021207697A1 (en) 2020-04-10 2021-10-14 Cantex Pharmaceuticals, Inc. Treatment of acute lung injury
EP4182452A1 (en) 2020-07-14 2023-05-24 Optimvia, LLC Methods for synthesizing non-anticoagulant heparan sulfate
KR20230058289A (en) 2021-10-21 2023-05-03 숙명여자대학교산학협력단 Combination therapy with griseofulvin for blood cancer

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2374910A1 (en) 1976-10-23 1978-07-21 Choay Sa PREPARATION BASED ON HEPARIN, INCLUDING LIPOSOMES, PROCESS FOR OBTAINING IT AND MEDICINAL PRODUCTS CONTAINING SUCH PREPARATIONS
US5804374A (en) 1980-12-05 1998-09-08 Massachusetts Insti. Technology Nuclear factors associates with transcriptional regulation
FR2553287B1 (en) 1983-10-18 1986-09-12 Choay Sa COMPOSITIONS BASED ON MUCOPOLYSACCHARIDES OR OLIGOSACCHARIDES, ESPECIALLY BASED ON HEPARIN FRACTIONS OR FRAGMENTS, SUITABLE FOR THE TREATMENT OF CELL PROLIFERATION DISORDERS
DE3422518A1 (en) 1984-06-16 1985-12-19 B. Braun Melsungen Ag, 3508 Melsungen HEPARIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEDICINAL PRODUCTS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF FATTY METABOLISM DISORDERS
FR2584606A1 (en) 1985-07-12 1987-01-16 Dropic USE OF POLY- AND OLIGOSACCHARIDES FOR THE PRODUCTION OF ACTIVE MEDICAMENTS IN THE PATHOLOGIES OF CONNECTIVE TISSUE
US5380716A (en) 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
IT1234826B (en) 1989-01-30 1992-05-29 Alfa Wassermann Spa HEPARIN DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION
US5399493A (en) 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
AU7681091A (en) 1990-04-05 1991-10-30 John R Hoidal Method and medicament for prevention or medication of human leucocyte elastase-mediated pulmonary diseases
US5250519A (en) 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
IT1254216B (en) 1992-02-25 1995-09-14 Opocrin Spa POLYSACCHARIDIC DERIVATIVES OF HEPARIN, EPARAN SULPHATE, THEIR FRACTIONS AND FRAGMENTS, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO1993019734A1 (en) 1992-04-02 1993-10-14 Baker Norton Pharmaceuticals, Inc. Method and composition for treating antigen-induced and exercise-induced asthma
US5668118A (en) 1992-07-24 1997-09-16 Cavalier Pharmaceuticals Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G
US5306724A (en) 1992-08-17 1994-04-26 Clintec Nutrition Company Method for preventing and treating atherosclerosis
GB2270841A (en) 1992-09-09 1994-03-30 Merck & Co Inc Compositions for Treating vascular restenosis
US5296471A (en) 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
US5696100A (en) * 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
WO1994018989A1 (en) 1993-02-22 1994-09-01 Cavalier Pharmaceuticals, Inc. Use of heparin to inhibit interleukin-8
SE9302135D0 (en) 1993-06-18 1993-06-18 Kabi Pharmacia Ab NEW PHARMACEUTICAL COMPOSITION
US5840707A (en) 1993-10-04 1998-11-24 Albany Medical College Stabilizing and delivery means of biological molecules
US5994318A (en) 1993-10-04 1999-11-30 Albany Medical College Cochleate delivery vehicles
EP0758247A4 (en) 1994-05-06 1997-08-20 Glycomed Inc O-desulfated heparin derivatives, methods of making and uses thereof
US5804560A (en) 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
EP0918461B1 (en) 1996-07-29 2004-10-27 Paringenix, Inc. Methods of treating asthma with o-desulfated heparin
US6154502A (en) 1996-08-22 2000-11-28 Intel Corporation Signal constellation slicer
US7258857B2 (en) 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
DE69814618T2 (en) 1997-02-15 2004-03-25 Millenium Pharmaceuticals, Inc., Cambridge TREATING INFARTS BY INHIBITING NF-KAPPAB
DE69821932T2 (en) 1997-05-30 2004-12-16 Arch Development Corp., Chicago P-SELECTIN TRANSLOCATION INTO VASCULAR EPITHELIAL LUMEN BY IONIZING RADIATION
US6406862B1 (en) 1998-10-06 2002-06-18 The United States Of America As Represented By The Secretary Of The Army Dip-stick assay for C-reactive protein
AU1477000A (en) 1998-11-13 2000-06-05 Eli Lilly And Company Method of treating heparin-induced thrombocytopenia
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US6153217A (en) 1999-01-22 2000-11-28 Biodelivery Sciences, Inc. Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
US6514502B1 (en) 1999-01-26 2003-02-04 Schering-Plough Veterinary Corporation Propagation of bovine cononavirus in chinese hamster ovary cells
EP1223948A2 (en) 1999-09-13 2002-07-24 CHARLOTTE-MECKLENBURG HOSPITAL doing business as Carolinas Medical Center Method of inhibiting nf-kappa-b with heparin, for treating cardiovascular diseases and inflammations
US7781416B2 (en) 2000-01-25 2010-08-24 Sigma-Tau Research Switzerland S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
US6489311B1 (en) 2000-05-02 2002-12-03 Charlotte-Mecklenburg Hospital Authoirty Method for the prevention of apoptosis
CA2444463C (en) * 2001-04-18 2012-03-20 Prometic Biosciences Inc. Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
EP1542704A1 (en) 2002-04-18 2005-06-22 Stephen H. Embury Method and composition for preventing pain in sickle cell patients
AU2003251829B2 (en) 2002-07-09 2009-12-10 Radical Therapeutix Method to inhibit ischemia and reperfusion injury
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
AU2003293122A1 (en) 2002-11-27 2004-06-23 Massachusetts Institute Of Technology Methods for synthesizing polysaccharides
US20040180812A1 (en) 2002-12-13 2004-09-16 Technology Center Methods of treating and preventing proliferative disease
ZA200508300B (en) 2003-05-20 2007-03-28 Transtech Pharma Inc RAGE antagonists as agents to reverse amyloidosis and diseases associated therewith
WO2005089365A2 (en) 2004-03-16 2005-09-29 The General Hospital Corporation Treatment and prevention of abnormal cellular proliferation
ES2388064T3 (en) * 2004-04-22 2012-10-08 Celator Pharmaceuticals, Inc. Liposomal formulations of anthracycline agents and cytidine analogues
US20050261241A1 (en) 2004-05-19 2005-11-24 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
US20050282775A1 (en) 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
US7468358B2 (en) 2004-06-16 2008-12-23 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome
US20060040896A1 (en) 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
JP2006076968A (en) 2004-09-10 2006-03-23 Seikagaku Kogyo Co Ltd Physiologically active molecule-containing crosslinked heparin gel composition
EP1906974A4 (en) 2005-07-22 2010-06-23 Univ California Heparin compostions and selectin inhibition
WO2007019554A2 (en) 2005-08-08 2007-02-15 Momenta Pharmaceuticals, Inc. Polysaccharides for delivery of active agents
US20100068192A1 (en) 2005-09-30 2010-03-18 Takara Bio Inc. Method for Production of T Cell Population
WO2007068076A1 (en) 2005-12-16 2007-06-21 Dnp Canada Inc. Chitin derivatives for hyperlipidemia
WO2007115372A1 (en) 2006-04-10 2007-10-18 Monash University A method of modulating beta-amyloid peptide production
WO2008073154A2 (en) 2006-07-26 2008-06-19 Intrexon Corporation Methods and compositions for treating disease
CA2663521A1 (en) 2006-09-20 2008-07-17 The Johns Hopkins University Combinatorial therapy of cancer and infectious diseases with anti-b7-h1 antibodies
CA2678587A1 (en) 2007-02-28 2008-09-04 Paringenix, Inc. O-desulfated heparins treating acute exacerbations of chronic obstructive pulmonary disease
EP2155188B1 (en) * 2007-06-01 2013-10-09 Abraxis BioScience, LLC Methods and compositions for treating recurrent cancer
EP2170354A1 (en) 2007-07-23 2010-04-07 University of Utah Research Foundation Method for blocking ligation of the receptor for advanced glycation end-products (rage)
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2009117677A2 (en) 2008-03-21 2009-09-24 University Of Utah Research Foundation Methods for controlling intracellular calcium levels associated with an ischemic event
JP5758797B2 (en) 2008-04-04 2015-08-05 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション Alkylated semi-synthetic glycosaminoglycan ethers and methods for their production and use
US8476249B2 (en) * 2009-05-07 2013-07-02 Glaxosmithkline Llc Method of treating thrombocytopenia
US20130034534A1 (en) 2009-09-29 2013-02-07 Philipp Kroneberg Method for treatment of patients with cystic fibrosis
EP2550004A4 (en) 2010-03-12 2014-07-02 Univ Australian Heparan sulfate replacement therapy
WO2011116954A2 (en) * 2010-03-24 2011-09-29 Bioréalités S.A.S. Prophylaxis of colorectal and gastrointestinal cancer
EP2588119A4 (en) 2010-06-28 2014-01-08 Stemtech Internat Inc Methods and compositions for enhancing stem cell mobilization
MX2013006020A (en) * 2011-01-31 2013-10-01 Celgene Corp Pharmaceutical compositions of cytidine analogs and methods of use thereof.
US20120196828A1 (en) 2011-02-01 2012-08-02 Paringenix, Inc. Sensitization of cancer cells to treatment
WO2013016181A1 (en) 2011-07-22 2013-01-31 Paringenix, Inc. Compositions and methods for anti-coagulation
WO2013166163A1 (en) 2012-05-01 2013-11-07 Duke University Compositions and methods for heparan sulfate as a biomarker for transplant rejection
HUE053247T2 (en) 2012-05-09 2021-06-28 Cantex Pharmaceuticals Inc Treatment of myelosuppression
EP4169533A1 (en) 2013-02-28 2023-04-26 President and Fellows of Harvard College Methods and compositions for mobilizing stem cells
AU2014340238A1 (en) 2013-10-22 2016-05-05 Cantex Pharmaceuticals, Inc. Methods of treating and preventing radiation damage
US20160296552A1 (en) 2013-10-24 2016-10-13 Cantex Pharmaceuticals, Inc. Treating Bacterial Infections of the Lung
WO2015142924A1 (en) 2014-03-17 2015-09-24 Cantex Pharmaceuticals, Inc. Multivalent cation formulations of partially desulfated heparins
US20160243168A1 (en) 2015-02-17 2016-08-25 Cantex Pharmaceuticals, Inc. Adoptive cell transfer methods
EP3258941A4 (en) 2015-02-17 2018-09-26 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
US20170106011A1 (en) 2015-10-20 2017-04-20 Cantex Pharmaceuticals, Inc. Methods of treating traumatic brain injury and sequelae
WO2017123549A1 (en) 2016-01-11 2017-07-20 Cantex Pharmaceuticals, Inc. Methods of treating or preventing graft-versus-host disease using hmgb1-interacting heparinoids

Also Published As

Publication number Publication date
US9271999B2 (en) 2016-03-01
PL2846809T3 (en) 2021-07-26
CL2014003017A1 (en) 2015-07-10
KR20200118510A (en) 2020-10-15
CN104411316A (en) 2015-03-11
IL235593A0 (en) 2015-01-29
HK1207574A1 (en) 2016-02-05
BR112014028094A2 (en) 2020-06-30
ES2848050T3 (en) 2021-08-05
EP3785720A1 (en) 2021-03-03
CA2872855C (en) 2021-07-27
JP6177885B2 (en) 2017-08-09
JP6448694B2 (en) 2019-01-09
US20180296590A1 (en) 2018-10-18
IL235593B (en) 2019-06-30
MX370567B (en) 2019-12-17
JP6726252B2 (en) 2020-07-22
DK2846809T3 (en) 2021-01-18
EP2846809A4 (en) 2015-12-30
EP2846809B1 (en) 2020-10-14
US11229664B2 (en) 2022-01-25
KR20150023361A (en) 2015-03-05
US8734804B2 (en) 2014-05-27
CA3122808A1 (en) 2013-11-14
EP2846809A1 (en) 2015-03-18
JP2019026647A (en) 2019-02-21
CL2021000008A1 (en) 2021-06-11
LT2846809T (en) 2021-01-25
SG10201603059YA (en) 2016-05-30
EA029382B1 (en) 2018-03-30
CN104411316B (en) 2018-05-01
CA2872855A1 (en) 2013-11-14
CN108498532B (en) 2021-07-23
MX2019009437A (en) 2019-10-02
PT2846809T (en) 2021-02-05
EA201492052A1 (en) 2015-08-31
JP2015521176A (en) 2015-07-27
US20220354882A1 (en) 2022-11-10
WO2013169355A1 (en) 2013-11-14
CN113521093A (en) 2021-10-22
HUE053247T2 (en) 2021-06-28
AU2013260101B2 (en) 2016-10-27
US20160213706A1 (en) 2016-07-28
SG11201407340YA (en) 2014-12-30
BR112014028094B1 (en) 2022-03-03
JP2017105850A (en) 2017-06-15
US20200038431A1 (en) 2020-02-06
MX2014013633A (en) 2015-07-06
CN108498532A (en) 2018-09-07
US20130303481A1 (en) 2013-11-14
AU2013260101A1 (en) 2014-12-18
US20130323230A1 (en) 2013-12-05
KR102452803B1 (en) 2022-10-07
KR102165348B1 (en) 2020-10-14

Similar Documents

Publication Publication Date Title
SG10201914117QA (en) Treatment Of Myelosuppression
IN2014DN09434A (en)
PH12014501561A1 (en) Therapeutically active compounds and their methods of use
MX363243B (en) Compositions and methods for treating cancer.
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
MX2015002669A (en) Methods of administering pirfenidone therapy.
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
MY181828A (en) Bicyclically substituted uracils and the use therapy
PH12014502513A1 (en) Nampt inhibitors
MX2014013752A (en) Nampt inhibitors.
MX353299B (en) Methods and compositions relating to p62 for the treatment and prophylaxis of cancer.
MX2015003701A (en) Treatment compositions.
TN2012000610A1 (en) Heterocyclic compounds, their preparation and their therapeutic application
PH12014500990A1 (en) Methods for treating gout flares
MX340536B (en) Egfr targeted therapy.
MX356317B (en) Treatment of symptoms associated with female gastroparesis.
PH12014502065A1 (en) Vesicular formulations
MX2013011694A (en) Taxane and abeo-taxane analogs.
IN2014DN03010A (en)
PH12015501210A1 (en) Use of pidotimod to treat psoriasis
PH12015501211A1 (en) Use of pidotimod to treat atopic dermatitis
AU2012240388A8 (en) Treatment regimens
MX2015001695A (en) Treatment regimens.
MY177715A (en) Use of pidotimod to treat atopic dermatitis
IL232661A0 (en) Method of treating pain by administration of nerve growth factor